Out of the Red and into the Black: John McCamant on Investment in Blood Cancer Companies
TICKERS: AMGN, ASTX, CELG, CYCC, DNDN, PCYC, RHHBY
October 25, 2012
Source: George S. Mack of The Life Sciences Report
Hematological cancers present special opportunities for investors. In this exclusive interview with The Life Sciences Report, John McCamant, editor of the Medical Technology Stock Letter, comments on several companies in the hematology/oncology space, describing the challenges and successes that influence investment in the sector. In the case of two companies with very different valuations, McCamant makes his preference clear. …read more